Supercharging AI for clinical development: our investment in PhaseV

When a new therapy finally reaches patients, it’s the outcome of decades of brilliant science and painstaking clinical work. Yet the journey is perilous: bringing a single drug to market can cost hundreds of millions of dollars, and more than 90% of clinical trials never cross the finish line. PhaseV was created to rewrite those odds. Already trusted by leading global pharmaceutical customers across more than 20 therapeutic areas including neurology, oncology, immunology, metabolic diseases, rare diseases, and more. The company's vertical AI platform has delivered substantial ROI to its customers by helping cut trial budgets by up to 50%, shorten enrolment and timelines by up to 40%, and lifting success rates by nearly a third.

Today, we’re delighted to announce a $50 million Series A investment in PhaseV, co-led with Insight Partners and with participation from Exor Ventures, LionBird, and Viola, bringing the company's total funding to $65 million. The round will fuel product expansion, deepen commercial partnerships and scale go-to-market efforts across the US, Europe and beyond.

We believe PhaseV can become the operating system for clinical trials—empowering every pharmaceutical, biotech and CRO to run smarter trials and bring breakthroughs to patients faster and with higher efficacy.

From our first conversations with the team, it was clear that PhaseV was carving out a new category. At its core is an adaptive-design engine capable of simulating millions of scenarios in minutes, paired with a causal-inference module that can tease apart hidden patient sub-groups and surrogate end-points that conventional statistics overlook. That ambitious vision is matched by founders who have lived the problem from multiple angles. CEO Raviv Pryluk completed a PhD at the Weizmann Institute before helping scale Immunai and CTO Elad Berkman led Via’s data-science organization as it expanded globally. Together, they have attracted a multidisciplinary bench of statisticians, clinicians, software engineers and drug-development veterans—people who understand both the rigor of clinical trials and the velocity of modern software. 

Early implementations with leading pharma and biotech partners have already shown that PhaseV can rescue stalled programs, focus resources on the patients most likely to benefit, and accelerate pivotal studies—all while fitting within existing regulatory frameworks.

To Raviv, Elad and the entire PhaseV team: welcome to the Accel family. We look forward to supporting you in building the future of clinical development!

‍